Scientists have produced the first pathoconnectome - an open access map for other researchers that shows how eye disease can alter retinal circuitry.
List view / Grid view
Filter the results
Scientists have found two active substances that allowed cells to reactivate the production of a protein that prevents the onset of Parkinson's disease.
Over the past year, BellBrook Labs has leveraged its Transcreener HTS Assay technology to build enabling products and services focusing on innate immunity targets.
By administering a one-time PTB antisense oligonucleotide therapy to mice, researchers observed an increase in neurons and elimination of Parkinson's from the models.
Japanese researchers have shown that a silicon-based antioxidant agent can suppress the development of kidney failure and Parkinson's disease in rodent models.
A molecular 'switch' that controls the immune machinery responsible for chronic inflammation has been identified which could help treat or even reverse the development of age-related conditions like Alzheimer's, Parkinson's, cancer and diabetes.
To address the receptor dysfunction associated with several neurological diseases, scientists have provided novel insights into a protein-protein interaction that could lead to more effective treatments.
A new drug-like compound has been developed which reportedly prevents the body from producing a protein that is often at the root of Parkinson's disease.
Molecular drivers of Parkinson's disease have been revealed by scientists who also determined how they impact the functions of genes involved in the condition and the results may point to potential new treatments.
Currently, there is no licensed treatment to slow or stop the progression of Parkinson’s disease. However, a team at Sheffield University in the UK are currently working to identify compounds that target the dopaminergic brain cells affected by the disease. Nikki Withers speaks to Dr Heather Mortiboys to hear how…
New research into sex-based differences of Parkinson's disease could lead to new treatments.
New discovery makes it possible to design new therapies to replace alpha-synuclein's function in people with Parkinson's disease.
A trial has begun in the US for the ENT-01 therapy treatment of Parkinson’s, with the first patient enrolled.
Arizona company claims their products can treat Lyme disease, diabetes, Parkinson’s disease and more, but have not been approved for any use.